The Hottest Drug Class in Oncology Just Got a Reality Check
ADC Therapeutics' lymphoma drug Zynlonta delivered three times as many patient deaths as the control arm in its key Phase 3 trial, despite hitting its efficacy target. The fallout could reshape how regulators evaluate the entire antibody-drug conjugate class.
27 Deaths, 9 Deaths, and One Very Uncomfortable Conversation
Imagine you're a restaurant with rave reviews for your new signature dish. Customers love the taste. Critics are buzzing. Then a health inspector shows up and finds something alarming in the kitchen.
That's roughly where antibody-drug conjugates (ADCs) find themselves right now. ADCs are a class of cancer drugs that work like guided missiles: an antibody finds the tumor, and a toxic payload destroys it. They've been the hottest trend in oncology for years, with tens of billions in M&A deals chasing the space. But a new safety signal from one of the class's marketed drugs is forcing an uncomfortable question: what if the missile isn't as precise as we thought?
ADC Therapeutics' Zynlonta (loncastuximab tesirine), a lymphoma drug approved in 2021, just delivered Phase 3 results that landed like a lead balloon. The LOTIS-5 trial tested Zynlonta plus rituximab against standard treatment in patients with relapsed diffuse large B-cell lymphoma (DLBCL), an aggressive blood cancer. The drug hit its main goal, showing it could slow disease progression better than the alternative.
But the safety data told a different story. 27 patients died in the Zynlonta arm. Only 9 died in the control arm.
The Numbers That Spooked Wall Street
Let's unpack why this matters, because progression-free survival (PFS) wins are supposed to be cause for celebration in oncology. The trial showed Zynlonta could delay the cancer from getting worse. That's real. That's meaningful for patients.
The problem is what happened next. Fatal side effects (what doctors call Grade 5 treatment-emergent adverse events) hit 13.2% of patients on Zynlonta, compared to just 4.6% on the standard treatment. That's nearly a three-to-one ratio. Most of these deaths occurred in patients 75 years or older, a population that's already fragile, but that's also exactly the population that gets DLBCL most often.
And here's the kicker: overall survival showed essentially . The hazard ratio came in around 0.96, which is statistician-speak for "basically the same." So you've got a drug that slows disease progression but doesn't help patients live longer, while carrying a significantly higher risk of fatal complications. That's a tough pitch to regulators, doctors, and patients alike.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
no benefit
Analysts didn't mince words. The death imbalance was enough to "obscure" any realistic path to broad second-line use, and the efficacy package was described as underwhelming given the safety cost.
This Isn't Zynlonta's First Warning Sign
The LOTIS-5 results didn't emerge from nowhere. A separate trial, LOTIS-9, had already been halted after testing Zynlonta plus rituximab in previously untreated, very elderly DLBCL patients. Among just 40 patients enrolled, 12 experienced serious respiratory events. Seven of those were fatal.
All seven patients who died were 80 years or older with significant health problems like COPD and pulmonary fibrosis. ADC Therapeutics argued that 6 of the 7 deaths were "unlikely or unrelated" to the drug. But the company still voluntarily paused the trial and notified regulators on both sides of the Atlantic. When you're volunteering to stop your own study, you know the optics aren't great.
Zynlonta's existing label already carries warnings about fatal infections (roughly 2% of patients), severe liver injury, and serious fluid retention including pleural effusion (fluid around the lungs) and even rare cases of cardiac tamponade, where fluid squeezes the heart. Edema and effusion showed up in 31% of patients in the pivotal LOTIS-2 trial. These aren't hidden risks; they're printed right on the box.
A Drug That Never Quite Found Its Groove
Commercially, Zynlonta has been treading water since launch. Annual sales have hovered in a narrow band: $74.9 million in 2022, dipping to $69.1 million in 2023, with approximately $73 million expected in 2025. For context, blockbuster cancer drugs measure their revenue in billions. Zynlonta reached brand profitability in 2024, but it has never been a growth story.
The drug still sits under accelerated approval, which is the FDA's way of saying, "We let you sell this early because early results looked promising, but you owe us a confirmatory trial." LOTIS-5 was supposed to be that trial. It was also supposed to unlock a label expansion into second-line treatment, opening the door to a much larger patient population.
Now, that door looks considerably harder to walk through. ADC Therapeutics says it plans to meet with the FDA and pursue a supplemental filing, but converting accelerated approval to full approval with a three-to-one death ratio on the books will require some very creative storytelling.
Why the Whole ADC Class Should Be Paying Attention
This is where the story gets bigger than one drug. ADCs are the darlings of oncology right now. Pfizer paid $43 billion for Seagen. AstraZeneca's Enhertu (trastuzumab deruxtecan) is rewriting the playbook in breast cancer. Dozens of ADCs are in clinical trials across nearly every tumor type.
But the class has always had a fundamental tension baked into its design. The "guided missile" analogy sounds great in investor presentations, but these missiles carry absurdly potent toxic payloads. When the payload detaches too early, or when the antibody isn't perfectly selective, healthy tissue gets caught in the crossfire. A recent meta-analysis found that 91.2% of ADC-treated patients experienced side effects, with 46.1% suffering serious ones.
Enhertu has its own well-documented issue with interstitial lung disease (inflammation and scarring in the lungs). Other ADCs have caused liver damage, blood count crashes, and eye problems. These aren't bugs in the system; they're features of a technology that straps chemical warheads to biological homing devices.
The Zynlonta signal is unlikely to derail the ADC revolution entirely. The class is too promising and too commercially valuable for that. But it could make regulators more conservative about approving ADCs in vulnerable populations, particularly elderly patients with other health problems. It could also raise the bar for confirmatory trials, pushing developers to show not just that their ADC slows tumor growth but that it actually helps people live longer.
The Bottom Line
Zynlonta's story is a cautionary tale wrapped inside a hype cycle. The drug works, at least by one measure; it genuinely delays disease progression. But in medicine, "it works" isn't enough if the cost is measured in lives rather than dollars.
For ADC Therapeutics, the path forward is narrow: convince the FDA that the benefit-risk profile still makes sense, potentially with tighter patient selection that excludes the most vulnerable elderly patients. For the broader ADC space, the lesson is simpler but harder to swallow: targeted therapy doesn't mean safe therapy. The missile still has to land cleanly, and right now, the collateral damage is impossible to ignore.
Clinical & Regulatory
5 min read
Thyroid Hormones for Depression? This Tiny Trial Just Made Big Pharma Pay Attention.
Autobahn Therapeutics just dropped Phase 2 data for a brain-targeted thyroid drug in bipolar depression, and the numbers are raising eyebrows. A tiny trial, no placebo arm, and yet the signal might be too strong to ignore.
